Skip to content
drillr.ai
Sign up

00460.HK

Sihuan Pharmaceutical Holdings Group Ltd.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK

HKD 0.71
−2.07%
Ask drillr

  • Oct 20, 2026, 08:58 UTC

    Hong Kong approved two Sihuan Pharmaceutical Holdings Group Ltd. products for marketing: an injectable polycaprolactone microsphere facial filler and an injectable sodium hyaluronate compound solution.

    Source:

  • Oct 9, 2026, 01:58 UTC

    Sihuan Pharmaceutical Holdings Group Ltd. and Sihuan Pharmaceutical Holdings Group Ltd. plan to cooperate on commercializing Sihuan Pharmaceutical Holdings Group Ltd.'s full-length triple-helix recombinant human collagen raw material.

    Source:

  • Oct 9, 2026, 01:58 UTC

    Sihuan Pharmaceutical said its subsidiary Sihuan Pharmaceutical Holdings Group Ltd. completed a strategic equity investment in Sihuan Pharmaceutical Holdings Group Ltd..

    Source:

  • Oct 5, 2026, 09:03 UTC

    Sihuan Pharmaceutical Holdings Group announced that five new specifications of its self-developed injectable sodium hyaluronate composite solution (brand name Dongyan) received approval from China's National Medical Products Administration for market launch.

    Source:

  • Sep 23, 2026, 10:40 UTC

    Sihuan Bioengineering announced it plans to apply to China Merchants Bank Wuxi Branch for a merger-and-acquisition loan of up to RMB 230 million to fund part of its acquisition of 65.6146% of Zhongrun Pharmaceutical and 80% of Changyuan Pharmaceutical.

    Source:

  • Aug 27, 2026, 14:14 UTC

    Sihuan Pharmaceutical repurchased 10 million shares from the market on August 27, 2026, at an average price of HKD 0.8111 per share, totaling approximately HKD 8.11 million.

    Source:

  • Aug 26, 2026, 04:13 UTC

    Sihuan Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 1.1612 billion, up 1.3% year-on-year, and net profit of RMB 224.7 million, up 119% year-on-year, with no dividend declared.

    Source:

  • Aug 26, 2026, 04:09 UTC

    Sihuan Pharmaceutical announced that executive director, deputy CEO and CFO Miao Guili resigned effective 2026-08-26, and Che Yuxuan was appointed non-executive director and Song Xiaomi was appointed CFO.

    Source:

  • Aug 12, 2026, 13:58 UTC

    Zhenkang Medical (02697.HK) announced it won the bid for a research equipment procurement project at Yunnan Agricultural University, supplying a multi-organ multi-sensor normothermic perfusion system with built-in ventilator for 2.8 million RMB.

    Source: